Zentalis Pharmaceuticals, Inc.
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment ofā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.65
Price-1.90%
-$0.09
1Y
Price
Market Cap
$331.017m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$124.133m
+9.4%
1y CAGR+23.3%
3y CAGR+11.7%
5y CAGREPS
-$1.73
+9.4%
1y CAGR+25.1%
3y CAGR+18.9%
5y CAGRBook Value
$182.680m
$253.066m
Assets$70.386m
Liabilities$38.651m
DebtDebt to Assets
15.3%
-0.3x
Debt to EBITDAFree Cash Flow
-$125.601m
-0.3%
1y CAGR+14.8%
3y CAGR+4.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company